Bio-Thera Solutions Valuation
Is 688177 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 688177 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 688177 (CN¥21.76) is trading below our estimate of fair value (CN¥78.12)
Significantly Below Fair Value: 688177 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 688177?
Key metric: As 688177 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 688177's PS Ratio? | |
|---|---|
| PS Ratio | 10.9x |
| Sales | CN¥825.18m |
| Market Cap | CN¥9.01b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 11.2x |
| Enterprise Value/EBITDA | -23.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 688177's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 10.3x | ||
600645 Vcanbio Cell & Gene Engineering | 5.7x | 9.3% | CN¥9.1b |
300406 Beijing Strong BiotechnologiesInc | 4.8x | 19.8% | CN¥8.4b |
688656 HOB Biotech GroupLtd | 22.5x | n/a | CN¥9.0b |
300685 Amoy Diagnostics | 8.4x | 20.4% | CN¥10.0b |
688177 Bio-Thera Solutions | 10.9x | 24.0% | CN¥9.0b |
Price-To-Sales vs Peers: 688177 is expensive based on its Price-To-Sales Ratio (10.9x) compared to the peer average (10.3x).
Price to Sales Ratio vs Industry
How does 688177's PS Ratio compare vs other companies in the CN Biotechs Industry?
| 1 Company | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
603716 Thalys Medical Technology Group | 0.9x | n/a | US$242.05m |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: 688177 is expensive based on its Price-To-Sales Ratio (10.9x) compared to the CN Biotechs industry average (7.4x).
Price to Sales Ratio vs Fair Ratio
What is 688177's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 10.9x |
| Fair PS Ratio | 6.7x |
Price-To-Sales vs Fair Ratio: 688177 is expensive based on its Price-To-Sales Ratio (10.9x) compared to the estimated Fair Price-To-Sales Ratio (6.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CN¥21.76 | CN¥31.00 +42.5% | 19.4% | CN¥37.00 | CN¥25.00 | n/a | 2 |
| Nov ’25 | CN¥22.54 | CN¥31.00 +37.5% | 19.4% | CN¥37.00 | CN¥25.00 | n/a | 2 |
| Oct ’25 | CN¥25.51 | CN¥31.00 +21.5% | 19.4% | CN¥37.00 | CN¥25.00 | n/a | 2 |
| Sep ’25 | CN¥19.96 | CN¥38.00 +90.4% | 34.2% | CN¥51.00 | CN¥25.00 | n/a | 2 |
| Aug ’25 | CN¥21.55 | CN¥42.10 +95.4% | 21.1% | CN¥51.00 | CN¥33.20 | n/a | 2 |
| Jul ’25 | CN¥21.08 | CN¥42.10 +99.7% | 21.1% | CN¥51.00 | CN¥33.20 | n/a | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Sichuan Kelun Pharmaceutical
CN¥49.3b
Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.
2422
CN¥32.66
7D
2.6%
1Y
14.2%
Dong-E-E-JiaoLtd
CN¥36.7b
Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.
423
CN¥58.18
7D
-0.4%
1Y
15.5%
China Resources Double-Crane PharmaceuticalLtd
CN¥21.2b
China Resources Double-Crane Pharmaceutical Co.,Ltd.
600062
CN¥21.11
7D
-5.1%
1Y
14.5%